ICON Public Limited Company

Equities

ICLR

IE0005711209

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 21:00:00 20/06/2024 BST			5-day change	1st Jan Change
316 ^USD	-0.83%		-0.60%	+11.63%

06-06	Transcript : ICON Public Limited Company Presents at Jefferies 2024 Global Healthcare Conference, Jun-06-2024 01:30 PM
05-31	Baird Adjusts Price Target on ICON to $367 From $363, Maintains Outperform Rating	MT

ICON Public Limited Company Reaffirms Earnings Guidance for the Year 2024

May 30, 2024 at 01:00 pm

ICON Public Limited Company reaffirmed earnings guidance for the year 2024. Full-year 2024 revenue guidance is reaffirmed in the range of $8,480 million - $8,720 million, representing a year over year increase of 4.4% to 7.4%.

Latest news about ICON Public Limited Company

Transcript : ICON Public Limited Company Presents at Jefferies 2024 Global Healthcare Conference, Jun-06-2024 01:30 PM	06-06
Baird Adjusts Price Target on ICON to $367 From $363, Maintains Outperform Rating	05-31	MT
Transcript : ICON Public Limited Company - Analyst/Investor Day	05-30
ICON Public Limited Company Reaffirms Earnings Guidance for the Year 2024	05-30	CI
Diamyd Medical AB Appoints ICON plc to Conduct Interim Analysis for the Phase 3 Trial	05-16	CI
ICON Prices $2 Billion Debt Offering	04-30	MT
ICON Public Limited Company Announces Pricing of USD 2 Billion Notes	04-30	CI
UBS Adjusts ICON Price Target to $380 From $368, Maintains Buy Rating	04-26	MT
ICON Seeks M&A	04-25	CI
Transcript : ICON Public Limited Company, Q1 2024 Earnings Call, Apr 25, 2024	04-25
ICON Q1 Adjusted EPS, Revenue Rise, 2024 Guidance Range Narrowed	04-24	MT
Earnings Flash (ICLR) ICON Reports Q1 EPS $3.47, vs. Street Est of $3.41	04-24	MT
Earnings Flash (ICLR) ICON Reports Q1 Revenue $2.09B, vs. Street Est of $2.088B	04-24	MT
Icon Public Limited Company Updates Earnings Guidance for the Year 2024	04-24	CI
ICON Public Limited Company Reports Earnings Results for the First Quarter Ended March 31, 2024	04-24	CI
Icon CFO Brennan to Depart for Outside Opportunity	04-03	DJ
Icon Says CFO Brennan Leaving in Q4, Reaffirms Guidance	04-03	MT
Brendan Brennan to Resign as Chief Financial Officer of ICON Public Limited Company in Fourth Quarter 2024	04-03	CI
Icon plc Reaffirm Earnings Guidance for the Year 2024	04-03	CI
Transcript : ICON Public Limited Company Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-12-2024 02:05 PM	03-12
Transcript : ICON Public Limited Company Presents at TD Cowen 44th Annual Health Care Conference 2024, Mar-05-2024 11:10 AM	03-05
Evercore ISI Adjusts Price Target on ICON to $350 From $325, Keeps Outperform Rating	02-23	MT
UBS Adjusts ICON Price Target to $368 From $295, Maintains Buy Rating	02-23	MT
Mizuho Securities Ups Price Target on ICON to $346 From $315, Keeps Buy Rating	02-23	MT
Barclays Adjusts Price Target on ICON to $355 From $325, Maintains Overweight Rating	02-23	MT

Chart ICON Public Limited Company

Duration

Period

More charts

Company Profile

ICON Public Limited Company is a healthcare intelligence and clinical research organization. The Company is engaged in providing outsourced services to pharmaceutical, biotechnology, medical device and government and public health organizations. It offers a range of specialized services to assist pharmaceutical, biotechnology and medical device companies to bring new drugs and devices to market faster. The Company's services include clinical research services, commercial positioning, consulting, early phase, strategic solutions, laboratories, language services, medical imaging, real world intelligence, site and patient solutions, COVID-19 clinical operation and decentralized and hybrid clinical solutions. It also provides its full range of clinical, consulting and commercial services across several sectors, which include biosimilars, biotechnology, government and public health solutions, medical devices and pharmaceuticals.

Sector

Biotechnology & Medical Research

Calendar

22/07/2024 - Annual General Meeting

More about the company

Income Statement Evolution

More financial data

Ratings for ICON Public Limited Company

Trading Rating

Investor Rating

ESG Refinitiv

B-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

316 USD

Average target price

363.6 USD

Spread / Average Target

+15.06%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
ICON PUBLIC LIMITED COMPANY	+11.63%	26.13B
MODERNA, INC.	+35.14%	51.51B
IQVIA HOLDINGS INC.	-7.43%	39.03B
LONZA GROUP AG	+35.88%	38.91B
CELLTRION, INC.	-10.62%	26.68B
ALNYLAM PHARMACEUTICALS, INC.	-17.77%	19.91B
UNITED THERAPEUTICS CORPORATION	+40.52%	13.71B
MEDPACE HOLDINGS, INC.	+30.70%	12.38B
BIO-TECHNE CORPORATION	-3.41%	11.74B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-11.32%	10.8B

Other Biotechnology & Medical Research